Poniard Pharmaceuticals, Inc. (PARD)
Stock Price: $0.0500 USD
-0.0100 (-16.67%)
Updated Jan 15, 2021 11:56 AM EST - Market closed
| Market Cap | 287,808 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 1.50M |
| EPS (ttm) | -3.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $0.0500 |
| Previous Close | $0.0600 |
| Change ($) | -0.0100 |
| Change (%) | -16.67% |
| Day's Open | 0.0500 |
| Day's Range | 0.0500 - 0.0500 |
| Day's Volume | 494 |
| 52-Week Range | 0.03 - 0.1 |
News
There are no news available yet.
About PARD
Poniard Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colore... [Read more...]
| Industry Biotechnology | IPO Date Aug 11, 1988 |
| Stock Exchange OTCMKTS | Ticker Symbol PARD |